- Home
- REGN vs ALL Comparison
REGN vs ALL Comparison
Compare REGN & ALL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- ALL
- Stock Information
- Founded
- REGN 1988
- ALL 1931
- Country
- REGN United States
- ALL United States
- Employees
- REGN N/A
- ALL N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- ALL Property-Casualty Insurers
- Sector
- REGN Health Care
- ALL Finance
- Exchange
- REGN Nasdaq
- ALL Nasdaq
- Market Cap
- REGN 63.4B
- ALL 54.4B
- IPO Year
- REGN 1991
- ALL 1993
- Fundamental
- Price
- REGN $490.28
- ALL $209.82
- Analyst Decision
- REGN Buy
- ALL Strong Buy
- Analyst Count
- REGN 23
- ALL 15
- Target Price
- REGN $891.17
- ALL $223.20
- AVG Volume (30 Days)
- REGN 1.5M
- ALL 1.2M
- Earning Date
- REGN 04-29-2025
- ALL 04-30-2025
- Dividend Yield
- REGN 0.36%
- ALL 1.91%
- EPS Growth
- REGN 16.49
- ALL 216.18
- EPS
- REGN 39.43
- ALL 14.64
- Revenue
- REGN $14,085,700,000.00
- ALL $65,299,000,000.00
- Revenue This Year
- REGN N/A
- ALL N/A
- Revenue Next Year
- REGN $6.97
- ALL $8.18
- P/E Ratio
- REGN $12.43
- ALL $14.34
- Revenue Growth
- REGN 7.52
- ALL 11.49
- 52 Week Low
- REGN $485.00
- ALL $156.66
- 52 Week High
- REGN $1,211.20
- ALL $212.91
- Technical
- Relative Strength Index (RSI)
- REGN 32.32
- ALL 61.12
- Support Level
- REGN $590.15
- ALL $204.00
- Resistance Level
- REGN $608.17
- ALL $207.87
- Average True Range (ATR)
- REGN 18.79
- ALL 3.89
- MACD
- REGN -3.82
- ALL 0.18
- Stochastic Oscillator
- REGN 3.98
- ALL 93.47
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.